These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11803082)

  • 1. Human therapeutic cocaine vaccine: safety and immunogenicity.
    Kosten TR; Rosen M; Bond J; Settles M; Roberts JS; Shields J; Jack L; Fox B
    Vaccine; 2002 Jan; 20(7-8):1196-204. PubMed ID: 11803082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine pharmacotherapy for the treatment of cocaine dependence.
    Martell BA; Mitchell E; Poling J; Gonsai K; Kosten TR
    Biol Psychiatry; 2005 Jul; 58(2):158-64. PubMed ID: 16038686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial.
    Kosten TR; Domingo CB; Shorter D; Orson F; Green C; Somoza E; Sekerka R; Levin FR; Mariani JJ; Stitzer M; Tompkins DA; Rotrosen J; Thakkar V; Smoak B; Kampman K
    Drug Alcohol Depend; 2014 Jul; 140():42-7. PubMed ID: 24793366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.
    Martell BA; Orson FM; Poling J; Mitchell E; Rossen RD; Gardner T; Kosten TR
    Arch Gen Psychiatry; 2009 Oct; 66(10):1116-23. PubMed ID: 19805702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
    Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
    Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial.
    Wagena EJ; de Vos A; Horwith G; van Schayck CP
    Nicotine Tob Res; 2008 Jan; 10(1):213-8. PubMed ID: 18188762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
    Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
    Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DBH gene as predictor of response in a cocaine vaccine clinical trial.
    Kosten TR; Domingo CB; Hamon SC; Nielsen DA
    Neurosci Lett; 2013 Apr; 541():29-33. PubMed ID: 23458673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
    Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cocaine vaccines: antibody protection against relapse.
    Kantak KM
    Expert Opin Pharmacother; 2003 Feb; 4(2):213-8. PubMed ID: 12562311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
    Overton ET; Lawrence SJ; Wagner E; Nopora K; Rösch S; Young P; Schmidt D; Kreusel C; De Carli S; Meyer TP; Weidenthaler H; Samy N; Chaplin P
    PLoS One; 2018; 13(4):e0195897. PubMed ID: 29652929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of ricin vaccine, RVEc™, in a Phase 1 clinical trial.
    Pittman PR; Reisler RB; Lindsey CY; Güereña F; Rivard R; Clizbe DP; Chambers M; Norris S; Smith LA
    Vaccine; 2015 Dec; 33(51):7299-7306. PubMed ID: 26546259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
    Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
    J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010.
    Kantak KM; Collins SL; Bond J; Fox BS
    Psychopharmacology (Berl); 2001 Jan; 153(3):334-40. PubMed ID: 11271406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.